James Ryan Mark | Fox Chase Cancer Center (2024)

• August 2000-May 2004 B.S. Biology with honors (magna cum laude), University of Missouri, Columbia, Missouri
• August 2005-May 2009 M.D. Saint Louis University School of Medicine, Saint Louis, Missouri
• July 2009-June 2010 Internship, General Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
• July 2010-June 2011 Resident in General Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
• July 2011-June 2015 Resident in Urologic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
• July 2015-July 2016 Fellow in Urologic Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina (Now Atrium Health)

• 2018 Diplomate, American Board of Urology
• 2018-Present DEA (New Jersey)
• 2017-Present New Jersey Unrestricted License No 25MA09973500
• 2018 American Board of Urology Qualifying Examination (Part 2),passed February 2018
• 2015 American Board of Urology Qualifying Examination (Part 1), passed July 2015
• 2015-2016 North Carolina Unrestricted License No 2015-00289
• 2011-Present Pennsylvania Unrestricted License No MD444134
• 2011-Present DEA (Pennsylvania)
• 2010 USMLE Step 3, passed October 2010
• 2009 USMLE Step 2 CS, CK passed January 2009
• 2007 USMLE Step 1, passed June 2007

• National Societies:
  American Urological Association
  American College of Surgeons
  Endourological Society
  European Association of Urology
  
• Local Societies:
  Philadelphia Urological Society
  Philadelphia County Medical Society

• 2019 Honorary Mention – Thomas Jefferson University Hospital Quality Improvement: Application of Alvimopan as a component of Enhanced Recovery After Surgery (ERAS) Protocol for patients undergoing Radical Cystectomy and Diversion (C&D)
• 2015 Philadelphia Region Robotic Olympics: Urology Gold Medal, Team Jefferson Gold Medal, Tournament Champions
• 2014 Mid Atlantic AUA 2014 Resident Forum Debate: Best Debater
• 2003 Phi Beta Kappa

1. Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, Gomella LG. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can J Urol. 2012 Apr;19(2):6227-31. PMID: 22512972.

2. Shenot PJ, Mark JR. Intradetrusor onabotulinumtoxinA injection: how I do it. Can J Urol. 2013;20(1):6649-6655. PMID: 23433140 

3. Mark JR, Kelly DC, Trabulsi EJ, Shenot PJ, Lallas CD. The effects of fatigue on robotic surgery skill training in Urology residents. J Robotic Surg. 2014;8(3):269-275. PMID: 276376894.

4. Mark JR, Gomella LG. Nonpalpable Intratesticular Mass in a Young Man with a History of Contralateral Retractile Testis. Oncology (Williston Park). 2017 Jun 15;31(6):484, 489-91. PMID: 28620904.

5. Mark JR, Hoffman-Censits J, Gomella LG. Basic Concepts in Bladder Cancer Immunotherapy. Am J Hematol Oncol. 2017;13:10.

6. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018;36:4, 414-424. PMID: 29236593

7. Truong H, Savard C, Den RB, Mark JR. Radiation Effect on Male Spermatogenesis and Fertility-The Science and Ethical Consideration of the Oregon and Washington Radiation Experiments on Prison Inmates. Urology. 2018 Nov;121:33-38. PMID: 30107187.

8. Mark JR, Kelly WK, Gomella LG. Re: Multidisciplinary clinical treatment of head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144:460-461. PMID: 29543958

9. Glick L, Chandrasekar T, Hubosky SG, Teplitsky S, Shah M, Leong JY, Ouma G, Mark JR. How I do it: Anticoagulation management for common urologic procedures. Can J Urol. 2020:27(6):10480-10487. PMID: 33325352

10. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019.. J Clin Oncol. 2020;38(4), 2798-2811. PMID: 32516092

11. Chandrasekar T, Glick L, Wong D, Han TM, Leong JY, Yi M, Mark JR, Mann MJ, Trabulsi EJ, Lallas CD. Simple frameshifts in minimally invasive surgery postoperative pain management significantly reduces opiate prescriptions. Can J Urol. 2020:27(3):10250-10256. PMID: 32544049

12. Mann MJ, Calio BP, Mark JR, Chelluri R, Hufnagel E, Reese A, Lallas CD, Trabulsi EJ, Chandrasekar T, Shenot PJ, Halpern E, Gomella LG. Hospital-specific antibiograms and antibiotic prophylaxis for prostate biopsies: a reexamination of AUA recommendations. Can J Urol. 2020;27(1):10099-10104. PMID: 32065866

13. Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, Godwin JL, McCue P, Hurwitz MD, Kelly WK, Lallas CD, Knudsen KE, Gomella LG, Dicker AP, Den RB. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):295-302. PMID: 31719663

14. Chandrasekar T, Han TM, Glick L, Leong JY, Teplitsky S, Noorani R, Holdberg H, Klaassen Z, Wallis CJD, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Setting the standards: Examining research productivity among academic urologists in the USA and Canada in 2019. Euro Urol Focus. 2021;7(2):489-496. PMID: 32113885

15. Salib A, Mark JR. DNA analysis for prostate specimen verification: How I do it. Can J Urol. 2021;28(1):10568-10573. PMID: 33625350

16. Mark JR, McDougal C, Giri V. Genetic testing guidelines and education of health care prostate providers involved in prostate cancer care. Urol Clin N Am. 2021;48:311-322. PMID: 34210487

17. Russo J, McDougal C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann MJ, Mark JR, Mille PJ, Preate D, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN. Pretest genetic education video versus genetic counseling for men considering prostate cancer germline testing: A patient-choice study to address urgent practice needs. JCO Precision Oncology. 2021;5:1377-1386. PMID: 34589662

18. Chandrasekar T, Bowler N, Schneider A, Goldberg H, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Outcomes of active surveillance for men with intermediate risk prostate cancer: A population-based analysis. Urology. 2021;155:101-109. PMID: 34186134

19. Chandrasekar T, Bowler N, Schneider A, Goldberg H, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. AUTHOR REPLY. Urology. 2021 Sep;155:109. PMID: 34488992

20. Uhr A, Glick L, Barron S, Zavodnick J, Mark JR, Shenot PJ, Murphy A. How I do it: PureWick female external catheter: a non-invasive urine management system for incontinent women. Can J Urol. 2021;28(3):10669-10672. PMID: 34129459

21. Shah YB, Clark CB, Shumaker A, Denisenko AA, Alfonsi S, Prebay Z, Schultz J, Mico V, Swaminathan V, Wang R, Mark JR, Trabulsi EJ, Lallas CD, Mann MJ, Goldberg H, Chandrasekar T. Does antithrombotic use enable earlier diagnosis of bladder cancer? A brief institutional assessment. Can J Urol. 2022 Dec;29(6):11391-11393. PMID: 36495582.

22. Gomella PT, Mark JR, Giri VN, Kelly WK, Gomella LG. Guidelines on Germline Testing for Urologic Tumor Syndromes. Eur Urol Focus. 2022;8(3):670-673. PMID: 35803854

23. Loeb S, Cheng HH, Leader A, Gross L, Sanchez-Nolasco T, Byrne N, Wise DR, Hollifeld L, Brown LH, Slater E, Pieczonka C, Gomella LG, Kelly WK, Trabulsi EJ, Handley N, Lallas CD, Chandrasekar TH, Mille P, Mann MJ, Mark JR, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri VN. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials. 2022;119:106821. PMID: 35710085

24. Mark JR, Gomella LG, Lallas CD, Smentkowski KE, Calvaresi A, Handley N, Den RB, Mille P, Tester WJ, Hoffman-Censits J, Dicker AP, Klonicke E, Halpern E, McCue P, Kelly WK, Trabulsi EJ. Enhancing bladder cancer care through the multidisciplinary clinic approach. Can J Urol. 2023 Jun;30(3):11526-11531. PMID: 37344462.

25. Chandrasekar T, Clark CB, Gomella A, Wessner CE, Wang S, Nam K, Liu JB, Forsberg F, Lyshchik A, Halpern E, Mark JR, Lallas CD, Gomella LG, Kania L, Trabulsi EJ, Eisenbrey JR. Volumetric Quantitative Contrast-enhanced Ultrasonography Evaluation of Complex Renal Cysts: An Adjunctive Metric to the Bosniak Classification System to Predict Malignancy. Eur Urol Focus. 2023 Mar;9(2):336-344. PMID: 36319560.

26. Chandrasekar T, Denisenko A, Mico V, McPartland C, Shah Y, Mark JR, Lallas CD, Fonshell C, Danella J, Jacobs B, Lanchoney T, Raman JD, Tomaszewski J, Reese A, Singer EA, Ginzburg S, Smaldone M, Uzzo R, Guzzo TJ, Trabulsi EJ. Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative. Urol Oncol. 2023 Aug;41(8):355.e1-355.e8. Epub 2023 Jun 23. PMID: 37357123.

27. Loeb S, Keith SW, Cheng HH, Leader A, Gross L, Sanchez-Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK, Lallas CD, Handley N, Mille PJ, Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. TARGET: A randomized, noninferiority trial of a pretest, patient-driven genetic education webtool versus genetic counseling for prostate cancer germline testing. Cancer Genetics. (in press)